Information about Secukinumab
Secukinumab is a human monoclonal antibody to interleukin-17A which acts as an immunosuppressant agent and is used to treat moderate to severe plaque psoriasis.
Liver safety of Secukinumab
Secukinumab has not been linked to serum enzyme elevations during therapy or to instances of idiosyncratic acute liver injury.
Mechanism of action of Secukinumab
Secukinumab (sek" ue kin' ue mab) is a recombinant, human IgG1 monoclonal antibody to interleukin (IL)-17A, a cytokine involved in the release of proinflammatory mediators. The binding of the monoclonal antibody blocks the interaction of IL-17A with its receptor and thus decreases immune and inflammatory pathways. Secukinumab is considered an immunomodulatory agent and has been evaluated in several immune mediated diseases. In large clinical trials in severe plaque psoriasis, secukinumab was shown to be beneficial and was subsequently approved for this use in the United States in 2015.
Secukinumab is available in single use vials, syringes and pens of 150 mg under the brand name Cosentyx. The typical dose is two 150 mg subcutaneous injections at weeks 0, 1, 2, 3 and 4 followed by every 4 weeks.
Side effects of Secukinumab
Side effects are not common, but can include upper respiratory symptoms, nausea and diarrhea. Rare, but potentially severe adverse reactions include severe infections, reactivation of tuberculosis, exacerbation of Crohn disease and immediate hypersensitivity reactions.
Monoclonal Antibodies IL-17A Antagonists